By Swaza
Introducing the first non-invasive nanofluid breathing aid for respiratory distress and advanced regenerative biomaterials for superior topical oxygen delivery – all powered by our nanotechnology platform. Swaza is pioneering a first-of-its-kind oxygen nanotherapy, enabling O₂ delivery and CO₂ removal through fibrotic lung tissue — without invasive ventilation. Our patented nanofluid technology is the only solution capable of dynamic gas exchange in compromised lungs, addressing a critical gap in respiratory care. With a $56B U.S. market opportunity, Swaza is poised to revolutionize treatment for millions suffering from hypoxemia, COPD, IPF, and other respiratory conditions.
SWAZA-1 is patented, breakthrough liquid nanoparticle technology featuring a unique set of physiochemical properties. Engineered for dynamic gas exchange, SWAZA-1 enables efficient oxygen delivery and carbon dioxide removal, even in severely compromised surface levels such as the lung, skin, and colon. Its liquid nanoparticles penetrate fluid and fibrotic barriers, even dense scar tissue and collagen-rich fluids, ensuring gas exchange even in conditions like IPF, COPD, and acute respiratory distress. First of its kind topical breathing aid capable of improving lung function without the use of oxygen tanks or ventilators. Absorbs large amounts of oxygen from ambient air and delivers a dramatically higher oxygen payload compared to natural lung fluid, ensuring critical oxygenation where traditional methods fail. Unlike mechanical ventilation, SWAZA-1 offers a portable, non-toxic solution that provides oxygen support without intubation. First of its kind - draws oxygen from the air. Actively shuttles gases through fluid and fibrotic barriers at the lung surface Advanced biomaterial for burns and ulcers. Emergency oxygenation for severe trauma. Enables delivery of molecules to the pulmonary system and across fibrotic barriers. Regenerative materials for medical aesthetic applications.
CATEGORY
